Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

Journal of Infectious Diseases

Volumn 179, Issue 5, 1999, Pages 1190-1196

  Burns, Jane L ^a,b,c,d   Van Dalfsen, Jill M ^a,b,c   Shawar, Ribhi M ^a,b,c   Otto, Kelly L ^a,b,c   Garber, Richard L ^a,b,c   Quan, Joanne M ^a,b,c   Montgomery, A Bruce ^a,b,c   Albers, Gary M ^a,b,c   Ramsey, Bonnie W ^a,b,c   Smith, Arnold L ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University of Missouri   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ASPERGILLUS; BACTERIAL FLORA; BACTERIUM ISOLATION; BRONCHITIS; CANDIDA ALBICANS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ASPERGILLUS; BACTERIA; CANDIDA ALBICANS; CHILD; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MICROBIAL; FORCED EXPIRATORY VOLUME; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM; TOBRAMYCIN;

EID: 0032968947     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314727     Document Type: Article

References (23)

1. 1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 1996 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation, 1997.
2. 2. Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991;4:35-51.
3. 3. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9.
4. 4. Ramsey BW, Pepe MS, Quan JM, et al. Chronic intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.
5. 5. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-6.
6. 6. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 1984;105:117-24.
7. 7. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985;132:761-5.
8. 8. Levy J, Smith AL, Kenny MA, Ramsey B, Schoenknecht FD. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J Infect Dis 1983;148: 1069-76.
9. 9. Smith AL, Ramsey BW, Hedges DL, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989;7:265-71.
10. 10. Eisenberg J, Pepe M, Williams-Warren J, et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest 1997;111:955-62.
11. 11. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-34.
12. 12. Burns JL, Emerson J, Stapp JR, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998;27: 158-63.
13. 13. Shigei J. Test methods used in the identification of commonly isolated aerobic gram-negative bacteria. In: Isenberg HD, ed. Clinical microbiology procedures handbook. Washington DC: American Society for Microbiology, 1992;1.19.1-1.19.110.
14. 14. American Thoracic Society. Standarization of spirometry. Am J Respir Crit Care Med 1995;152:1107-36.
15. 15. Barends DM, Zwaan CL, Hulshoff A. Micro-determination of tobramycin in serum by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1981;225:417-26.
16. 16. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 3rd ed; approved standard. Wayne, PA: NCCLS, 1993.
17. 17. Stutman HR, Marks MI. Antibiotic prophylaxis in CF [abstract]. Monatsschr Kinderheilkd 1996;144:1028-51.
18. 18. Michel BC. Antibacterial therapy in cystic fibrosis. Chest 1988;94:129S-40S.
19. 19. Ramsey BW, Smith AL. Response to letter to the editor: aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;329:1660.
20. 20. Mroueh S. Spock A. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Chest 1994;105:32-6.
21. 21. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-8.
22. 22. Barclay ML, Begg EJ, Chambers ST, Thornley PE, Pattemore PK, Grimwood K. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother 1996;37:1155-64.
23. 23. Acar JF, Goldstein FW. Disk susceptibility test. In: Lorian, V, ed. Antibiotics in laboratory medicine. 4th ed. Baltimore: Williams & Wilkins, 1996:1-51.